Paid Clinical Trials Greenville
Discover 426 paid clinical trials in Greenville, South Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
The Arteriovenous Vascular (AV) ACCESS TrialThe Arteriovenous Vascular (AV) ACCESS Trial
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT04646226
Conditions
End-Stage Kidney Disease
Hemodialysis Complication
Eligibility Criteria
Sex: All
Age: 60+
Healthy Volunteers: Not accepted
Interventions
AV graft
surgical intervention for creation of a fistula
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT05026866
Conditions
Alzheimer Disease
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Not accepted
Interventions
Donanemab
Placebo
Primary Subtalar Arthrodesis for Calcaneal FracturesPrimary Subtalar Arthrodesis for Calcaneal Fractures
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT06249126
Conditions
Calcaneus Fracture
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)
Open Reduction Internal Fixation (ORIF) only
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by BayerStudy to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Sponsor:
Bayer
Location:
Code:
NCT04464226
Conditions
Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Darolutamide (Nubeqa, BAY1841788)
A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaA Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
Sponsor:
AstraZeneca
Location:
Code:
NCT06502366
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BDA MDI HFO 160/180 μg
BDA MDI HFA 160/180 μg
Placebo MDI HFA
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004
Sponsor:
Intec Pharma Ltd.
Location:
Code:
NCT02615873
Conditions
Parkinson's Disease
Eligibility Criteria
Sex: All
Age: 30 - 70+
Healthy Volunteers: Not accepted
Interventions
Accordion Pill™ Carbidopa/Levodopa
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTNSPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Sponsor:
Medtronic Vascular
Location:
Code:
NCT05198674
Conditions
Hypertension
Vascular Diseases
Cardiovascular Diseases
Chronic Kidney Diseases
Diabetes Mellitus
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Renal Denervation (Symplicity Spyral™)
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsTesting the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04530565
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Blinatumomab
Bone Marrow Aspiration and Biopsy
Cyclophosphamide
Cytarabine